TPST Logo

Tempest Therapeutics, Inc. (TPST) 

NASDAQ$0.855
Market Cap
$37.31M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
298 of 924
Rank in Industry
171 of 527

TPST Insider Trading Activity

TPST Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$100,001360
Sells
$967,033240

Related Transactions

Brady Stephen RPresident and CEO1$73,8500$0$73,850
Trojanowski JustinCorporate Controller1$16,2000$0$16,200
Whiting SamuelChief Medical Officer1$9,9510$0$9,951
Versant Venture Capital VI, L.P.10 percent owner0$02$967,033$-967,033

About Tempest Therapeutics, Inc.

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was â€¦

Insider Activity of Tempest Therapeutics, Inc.

Over the last 12 months, insiders at Tempest Therapeutics, Inc. have bought $100,001 and sold $967,033 worth of Tempest Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Tempest Therapeutics, Inc. have bought $1.71M and sold $967,033 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Brady Stephen R (President and CEO) — $73,850. Trojanowski Justin (Corporate Controller) — $16,200. Whiting Samuel (Chief Medical Officer) — $9,951.

The last purchase of 35,000 shares for transaction amount of $73,850 was made by Brady Stephen R (President and CEO) on 2024‑07‑03.

List of Insider Buy and Sell Transactions, Tempest Therapeutics, Inc.

2024-08-12SaleVersant Venture Capital VI, L.P.10 percent owner
387,999
2.043%
$1.10$426,993-1.24%
2024-08-08SaleVersant Venture Capital VI, L.P.10 percent owner
400,000
1.814%
$1.35$540,040-29.44%
2024-07-03PurchaseBrady Stephen RPresident and CEO
35,000
0.1539%
$2.11$73,850-53.29%
2024-07-02PurchaseWhiting SamuelChief Medical Officer
4,672
0.0207%
$2.13$9,951-53.17%
2024-06-28PurchaseTrojanowski JustinCorporate Controller
7,500
0.0338%
$2.16$16,200-53.88%
2022-04-29PurchaseWoiwode Thomas
2.12M
11.9674%
$2.36$5M-44.60%
2022-01-07PurchaseDubensky Thomas W.President
2,000
0.0288%
$4.78$9,560-47.73%
2022-01-06PurchaseWhiting SamuelChief Medical Officer
1,700
0.0243%
$4.80$8,168-48.40%
2016-06-01PurchaseDipp MichelleChief Executive Officer
425,000
1.3568%
$7.00$2.98M-53.63%
2016-06-01PurchaseALDRICH RICHARDdirector
425,000
1.3568%
$7.00$2.98M-53.63%
2016-05-18PurchaseDipp MichelleChief Executive Officer
20,000
0.0671%
$7.86$157,200-53.14%
2016-05-18PurchaseALDRICH RICHARDdirector
20,000
0.0671%
$7.86$157,200-53.14%
2016-05-17PurchaseDipp MichelleChief Executive Officer
20,000
0.0677%
$7.56$151,200-50.67%
2016-05-17PurchaseALDRICH RICHARDdirector
20,000
0.0677%
$7.56$151,200-50.67%
2016-05-16PurchaseDipp MichelleChief Executive Officer
20,000
0.0668%
$7.69$153,800-51.69%
2016-05-13PurchaseDipp MichelleChief Executive Officer
16,295
0.055%
$7.06$115,043-46.48%
2016-05-13PurchaseALDRICH RICHARDdirector
16,295
0.055%
$7.06$115,043-46.48%
2016-05-12PurchaseDipp MichelleChief Executive Officer
19,800
0.0679%
$6.84$135,352-43.52%
2016-05-12PurchaseALDRICH RICHARDdirector
19,800
0.0679%
$6.84$135,352-43.52%
2016-05-11PurchaseDipp MichelleChief Executive Officer
20,000
0.0709%
$7.64$152,800-47.08%
Total: 98
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Brady Stephen RPresident and CEO
46376
0.1063%
$39,651.4810
Trojanowski JustinCorporate Controller
22168
0.0508%
$18,953.6410
Whiting SamuelChief Medical Officer
9573
0.0219%
$8,184.9220<0.0001%
Westphal Christoph H
3820571
8.7543%
$3.27M20
Longwood Fund, L.P.10 percent owner
3820571
8.7543%
$3.27M20
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

Tempest Therapeutics, Inc.
(TPST)
$22,186,116
57
-43.73%
$37.31M
$140,938,207
36
14.75%
$41.76M
$23,895,365
34
-37.28%
$37.97M
$241,165
22
-16.72%
$40.55M
$167,476,357
20
-1.54%
$41.64M

TPST Institutional Investors: Active Positions

Increased Positions22+66.67%5M+171.18%
Decreased Positions12-36.36%929,854-32.7%
New Positions14New4MNew
Sold Out Positions7Sold Out803,479Sold Out
Total Postitions43+30.3%7M+138.48%

TPST Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Versant Venture Management, Llc$2,946.007.97%3.51M+4MNew2024-12-31
Blackrock, Inc.$464.001.25%551,861+274+0.05%2024-12-31
Jane Street Group, Llc$414.001.12%493,094+493,094New2024-12-31
Fmr Llc$363.000.98%431,93200%2024-12-31
Geode Capital Management, Llc$298.000.81%354,276+134,209+60.99%2024-12-31
Ubs Group Ag$164.000.45%195,676+187,281+2,230.86%2024-12-31
Millennium Management Llc$159.000.43%189,506+189,506New2024-12-31
Vanguard Group Inc$148.000.4%176,19300%2024-12-31
Xtx Topco Ltd$135.000.37%160,807+136,818+570.34%2024-12-31
Fil Ltd$109.000.29%129,57900%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.